Introduction
Apolipoprotein A-I (apoA-I) is the major structural protein of high density lipoprotein (HDL) particles and, as a co-factor of lecithin-cholesterol acyltransferase, is involved in the esterification of free cholesterol [1, 2] . ApoA-I plays an essential role in cholesterol efflux from peripheral cells and in the reverse cholesterol transport process. Several epidemiological studies have reported that HDL-cholesterol levels are inversely related to cardiovascular disease including the incidence of coronary heart disease (CHD) [3] [4] [5] .
Weekly infusions of apoA-I Milano, a mutant version of apoA-I found in subjects with low HDL-cholesterol, but not increased risk of vascular disease, for 5 weeks was found to regress, coronary atheroma volume in patients hospitalised with acute coronary syndromes [6] . These studies further support a role for apoA-I and HDL-cholesterol in the pathogenesis of cardiovascular disease.
The regulation of HDL levels is a complicated and incompletely understood process, and is likely to depend on the interaction of both environmental and genetic factors. Several genetically determined structural variants of apoA-I have been identified, and have allowed the characterisation of structure-function relationships in the protein [7] .
A G→A mutation at position -75 of the apoA-I gene promoter occurs at a frequency of about 0.18 in Caucasian populations and has been associated with higher plasma HDLcholesterol levels in several ethnic groups [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] . In vitro [18] and in vivo studies [15] [16] [17] have shown that the A substitution is associated with increased apoA-I gene expression, and elevated plasma apoA-I and HDL-cholesterol concentrations. Up-regulation of the apoA-I promoter may lead to increased HDL production and increased very low-and low-density lipoprotein (LDL) clearance. Previous studies also showed an association between the apoA-I polymorphism and plasma triglyceride levels, the triglyceride level being lower in men with -75A [14, 19] .
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A further MspI polymorphic site has been identified in the first intron of the apoA-I gene [20] , in which two consecutive transitions at +83 bp (C to T) and +84 bp (G to A) sites occur together or independently. Several studies have shown that these transitions are also associated with increased HDL-cholesterol levels in Caucasians [21] . The frequency of the +83 bp substitution in a healthy Caucasian population was lower (rare allele frequency: 0.04) than that at the -75 bp site [21] . However, some studies reported that patients with the base changes at -75 and/or +83 bp of the apoA-I gene have more severe CHD in both Caucasian and Chinese populations [21, 22] . In those studies, base changes at -75 and +83 bp of the apoA-I gene were not associated with increased HDL-cholesterol levels.
In the present study we investigated the two MspI polymorphisms (G-75A and C83T)
to assess their importance, with respect to plasma lipid levels and blood pressure in Chinese subjects with hypertension and non-hypertensive controls.
Methods
The study was approved by the Clinical Research Ethics Committee of the Chinese University of Hong Kong. All 271 subjects gave written informed consent and were of Han Hg after repeated measurement in a quiet environment or were receiving anti-hypertensive treatment. Only 10% of the hypertensive subjects were receiving treatment. All subjects with impaired fasting glucose or diabetes (fasting plasma glucose ≥6.1 mmol/L) were excluded.
DNA was extracted from peripheral blood from the 271 Hong Kong Chinese subjects.
The apoA-I gene C83T and G-75A polymorphisms were screened using a PCR-based RFLP protocol [14] . 
Results
A total of 271 non-diabetic, normotriglyceridaemic Chinese subjects were recruited for the study. The demographic characteristics of the control and hypertensive subjects are described in Table 1 . The hypertensive group (B) not only had higher blood pressure but also higher indices of obesity, and a more adverse lipid profile than the control group A.
No differences were identified in the frequency distributions of the ApoA-I G-75A genotypes or alleles between the control (group A) and hypertensive subjects (group B).
However, there was a significantly lower frequency of the CT genotype (p=0.012) and T allele (p=0.011) in the hypertensive subjects (group B). Similarly, blood pressure and triglyceride levels were significantly lower and HDL-cholesterol was significantly higher in the subjects with the CT genotype compared to those with the CC genotype (p<0.05 for all, Table 2 ). However, the G-75A genotypes did not appear to be associated with the lipid or blood pressure levels.
From the zero order correlation analyses, the apoA-I C83T polymorphism correlated with HDL-cholesterol (β=0.14, p=0.029), triglycerides (β=-0.17, p=0.006), systolic (β=-0.15, p=0.018) and diastolic blood pressure (β=-0.12, p=0.056). Partial correlation adjustment for gender had no effect on the strength of the correlation, but after adjustment for age and gender the relationship with systolic blood pressure was no longer significant (β=-0.10, p=0.12), but remained significant for HDL-cholesterol (β=0.13, p=0.047), and triglycerides (β=-0.12, p=0.043). Data previously reported from Caucasian subjects (n=534), where the frequency of the GG, GA, and AA genotypes were 65.7, 32.0, and 2.3%, respectively, with an allele frequency of 81.7, and 18.3%, for the G and A alleles, were significantly different compared to the distribution within the current control population (group A, Table 2 , p<0.001) [12] .
Whereas no differences were observed for the C83T polymorphism, whose frequencies in Caucasians were 93.4, 6.6% for the CC and CT genotypes and 96.7, 3.3% for the C and T alleles [12] .
Discussion
The prevalence of hypertension and dyslipidaemia is high in Hong Kong. In the adult population of Hong Kong Chinese, 46% of men and 41% of women have plasma cholesterol levels over 5.2 mmol/L. 18% of men and 17% of women have hypertension (≥140/90 mm Hg) [23] . Many genetic and environmental factors are involved in regulation of lipid levels and blood pressure. The apoA-I gene, which is a major structural component of HDL, is a possible candidate associated with changes in lipid metabolism. Epidemiological and clinical studies have revealed an inverse correlation between plasma HDL-cholesterol concentration and CHD incidence [24] [25] [26] . Furthermore, a strong genetic regulation of the level of HDLcholesterol has been established in several studies [25, 27] . In an effort to elucidate the functional role of apoA-I gene polymorphisms, we examined a putative association between two apoA-I/MspI polymorphisms and plasma lipid levels, and explored their relationship with other clinical parameters.
In vitro and in vivo studies suggest that the A allele at -75 site increases apoA-I gene expression and hence leads to elevated plasma apoA-I and HDL-cholesterol concentrations [14] [15] [16] 18, 28] . Conversely, the A allele has also been reported to be associated with decreased apoA-I gene expression in vitro [29] . The base substitution at the 83 bp site of the apoA-I gene has also been reported to be associated with elevated HDL-cholesterol levels [21] . In our present study, the 83T allele was associated with higher HDL-cholesterol levels, supporting the association of this gene with modulating HDL-cholesterol levels, even though there was no evidence of a relationship with the G-75A polymorphism. The apoA-I C83T polymorphism was not an independent predictor of HDL-cholesterol levels. However, regression equations are designed to explain the largest proportion of the variance in the model, rather than identifying biologically relevant parameters involved in disease pathogenesis. As such, waist circumference, an independent predictor of all the lipid and blood pressure parameters, gender, or age may act as composite markers of a number of cardiovascular risk factors, and therefore appear as strong independent predictors in these analyses. Similarly, exclusion of a parameter does not preclude it from directly contributing to the pathogenesis of the disorder, merely the variance attributed to the parameter is accounted for by the other variables. In our cross-sectional analyses, BMI closely correlated with all blood pressure and lipid parameters, but was not an independent predictor in the regression analyses, probably confounded by other parameters such as increasing waist circumference and ageing. It is therefore not surprising that the apoA-I C83T polymorphism with its small effect size, and the likely interactions with other genetic and environmental factors, is not an independent predictor of HDL-cholesterol levels, even though the polymorphism correlated with HDL-cholesterol and triglyceride levels even after adjustment for age and gender.
The previous studies reported that the frequency of the -75A allele and the +83T in
Caucasian populations is about 18% and 4%, respectively [8, 12, 15, 16, 21] . As a distinct group, the Hong Kong Chinese healthy controls (group A) had a significantly higher -75A allele frequency (31.1%) than in equivalent Caucasian populations. This suggests the genetic background could be responsible for the variable results.
Plasma triglyceride levels were significantly different between the C83T genotypes,
showing decreased levels in the heterozygote subjects. Thus, the rare T allele was associated with lower plasma triglyceride levels. Mutations in the apoAI-CIII-AIV gene cluster have been implicated in hypertriglyceridaemia. The A allele at -75 bp site of apoA-I gene was associated with lower triglyceride levels in men in Finnish population [14] , but not in Japanese [10] or in the current study. However, the association of the 83T allele with decreased triglyceride levels suggests this locus may modulate triglyceride levels in Oriental subjects.
Our study also found a relationship between the C83T polymorphism of the apoA-I gene and blood pressure. The T allele frequency was significantly lower in the affected subjects (group B) than that in control subjects (group A) and the subjects with the CT genotype had significantly lower SBP and DBP than subjects with CC genotype. Blood pressure is influenced by genetic and nongenetic factors. Other candidate genes in lipoprotein metabolism have been suggested to be candidates for blood pressure variation including the apoB gene which was reportedly associated with SBP [30] . The D8S282 marker near LPL gene locus has also been reported to be associated with SBP variation in
Taiwanese [31] and in our population [32] . Furthermore, a previous study in Caucasians also suggested a possible role for the apoAI-CIIII-AIV gene complex in blood pressure [33] . Our findings support the close relationship between blood pressure and lipid metabolism.
However, it is currently unclear how such a mutation might influence blood pressure but these polymorphisms might be in linkage with others which may be more clearly related to blood pressure.
In summary, we conclude that the allele distribution of the ApoA-I/MspI G-75A polymorphism is significantly different between Chinese and Caucasian populations. The G-75A polymorphism did not appear to be associated with plasma HDL-cholesterol levels in Hong Kong Chinese. However, the 83T allele appears to be associated with higher HDLcholesterol levels and decreased triglyceride levels and blood pressure. The interesting situation with the apoA-I gene in linking lipid metabolism and blood pressure requires further investigation to elucidate the mechanisms underlying this relationship. 
